After properly establishing the role of VCAM-1 in atherogenesis as a mediator of pathological monocyte infiltration,59–62 novel therapeutics blocking VCAM-1 function have emerged as an attractive strategy for treating atherosclerosis. Here, VCAM1 is linked to atherosclerosis.